Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis

Prognostic factors for skeletal complications from metastatic bone disease in breast cancer

(2010) Janet E. Brown et al.   BREAST CANCER RESEARCH AND TREATMENT

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

(2010) Giannis Mountzios et al.   Translational Research

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The critical role of the bone microenvironment in cancer metastases

(2009) Sandra Casimiro et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid

(2009) Michael Lein et al.   PROSTATE

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

(2008) Allan Lipton et al.   CANCER